In Cell Art expands research collaboration with sanofi

09 Dec 2009 | News

Collaboration

In Cell Art, a specialist in the drug-delivery of siRNA, DNA and protein drugs, has  expanded its research collaboration agreement with Sanofi Pasteur, the vaccines division of Sanofi Aventis Group. Under the agreement In Cell Art’s nanocarrier technologies will be evaluated for use in of Sanofi Pasteur’s vaccines programme.

“This agreement highlights [the potential of] In Cell Art’s nanocarrier technologies for new vaccine development,” said Chloé Bellocq, CEO, and Bruno Pitard, co-founder of In Cell Art.

The Nantes-based company’s ICA614 nanocarrier, formulated from synthetic DNA, features a dramatic enhancement of the immunogenicity of plasmid DNA-encoding tumour or pathogen-derived antigens, a reduction of the dose of plasmid DNA, and an excellent safety profile.  

ICA614 is currently in use, or being tested, by other vaccine development companies, for use in DNA vaccines. It has also been shown to increase the immunogenicity of subunit vaccines.

Never miss an update from Science|Business:   Newsletter sign-up